explore -WSS

explore

author：entertainment 2025-09-30 18:20:32 - browse：494

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Cancer drug shortages should be causing more outrage
Next article： JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

WSS

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Risky weight loss products often used by teens globally, per study

Neurocrine congenital adrenal hyperplasia trial succeeds

Heart disease and mental health: A look at cardiac psychology

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

hotspot

explore

leisure time

Alkermes shareholders re

Covid’s new normal has set in amid another rise in cases

In Memoriam: Notable people who died in 2023

Doulas covered by Medicaid under New York's new plan

Activists slam private health insurers over coverage restrictions

What happened to the House vote on health price transparency?

United colonoscopy coverage change 'may cost lives,' doctors say

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Novavax promises a turnaround & Lilly roils the obesity market

Risky weight loss products often used by teens globally, per study

leisure time

How the messy conversation about Dolly changed bioethics

Why the drug industry's warnings on the IRA's impact fall short

Doulas covered by Medicaid under New York's new plan

Why the drug industry's warnings on the IRA's impact fall short

Free Covid tests will again be offered to all U.S. households

The unintended consequences of overturning Roe v. Wade

focus

entertainment

hotspot

focus